The Effect of Fimasartan, an Angiotensin Receptor Type 1 Blocker, on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Korean Male Volunteers: A One-Sequence, Two-Period Crossover Clinical Trial-Reference-Cited by-同舟云学术

The Effect of Fimasartan, an Angiotensin Receptor Type 1 Blocker, on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Korean Male Volunteers: A One-Sequence, Two-Period Crossover Clinical Trial

Published:2012-07 Issue:7 Volume:34 Page:1592-1600
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Gu Namyi,Kim Bo-Hyung,Lim Kyoung Soo,Kim Sung Eun,Nam Won Seok,Yoon Seo Hyun,Cho Joo-Youn,Shin Sang-Goo,Jang In-Jin,Yu Kyung-Sang

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference32 articles.

1. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects;Chi;Am J Cardiovasc Drugs,2011

2. Efficacy and Tolerability of Fimasartan, a New Angiotensin Receptor Blocker, Compared With Losartan (50/100 mg): A 12-Week, Phase III, Multicenter, Prospective, Randomized, Double-Blind, Parallel-Group, Dose Escalation Clinical Trial With an Optional 12-Week Extension Phase in Adult Korean Patients With Mild-to-Moderate Hypertension

3. Angiotensin II receptor blockers;Barreras;Proc (Bayl Univ Med Cent),2003

4. Fimasartan;Am J Cardiovasc Drugs,2011

5. The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers;Shin;J Cardiovasc Pharmacol,2011

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

A Pharmacokinetic Drug Interaction Between Fimasartan and Linagliptin in Healthy Volunteers

;Drug Design, Development and Therapy;2020-05

2. Development of a Korean‐specific virtual population for physiologically based pharmacokinetic modelling and simulation;Biopharmaceutics & Drug Disposition;2019-04

3. PK/PD evaluation of fimasartan for the treatment of hypertension Current evidences and future perspectives;Expert Opinion on Drug Metabolism & Toxicology;2018-05-04

4. Role of cytochrome P450 enzymes in fimasartan metabolism in vitro;Food and Chemical Toxicology;2018-05

5. Pharmacological Profiles of a Highly Potent and Long-Acting Angiotensin II Receptor Antagonist, Fimasartan, in Rats and Dogs after Oral Administration;Biological & Pharmaceutical Bulletin;2017